News | February 17, 2021
Steady quarter with margin improvement for Glenmark: ICICI Securities
India business grew 11.8% YoY vs mid-single digit industry growth.
India business grew 11.8% YoY vs mid-single digit industry growth.
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
The pandemic has provided tailwinds in terms of access to rural healthcare and India’s emergence as a vaccine powerhouse
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
_256_384.jpg)
Indian Chemical News, an online news media covering Pharma, Chemical and Petrochemical sector is organizing an E-conference on “India's Pharma Industry Outlook 2021” on 12th February, 2021 from 3:00 PM – 4:30 PM.
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Subscribe To Our Newsletter & Stay Updated
